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Abstract
Objective: Development and validation of a selective and sensitive LCMS method for the determination of methotrexate
polyglutamates in dried blood spots (DBS).
Methods: DBS samples [spiked or patient samples] were prepared by applying blood to Guthrie cards which was then dried
at room temperature. The method utilised 6-mm disks punched from the DBS samples (equivalent to approximately 12 ml of
whole blood). The simple treatment procedure was based on protein precipitation using perchloric acid followed by solid
phase extraction using MAX cartridges. The extracted sample was chromatographed using a reversed phase system
involving an Atlantis T3-C18 column (3 mm, 2.16150 mm) preceded by Atlantis guard column of matching chemistry.
Analytes were subjected to LCMS analysis using positive electrospray ionization.
Key Results: The method was linear over the range 5–400 nmol/L. The limits of detection and quantification were 1.6 and
5 nmol/L for individual polyglutamates and 1.5 and 4.5 nmol/L for total polyglutamates, respectively. The method has been
applied successfully to the determination of DBS finger-prick samples from 47 paediatric patients and results confirmed with
concentrations measured in matched RBC samples using conventional HPLC-UV technique.
Conclusions and Clinical Relevance: The methodology has a potential for application in a range of clinical studies (e.g.
pharmacokinetic evaluations or medication adherence assessment) since it is minimally invasive and easy to perform,
potentially allowing parents to take blood samples at home. The feasibility of using DBS sampling can be of major value for
future clinical trials or clinical care in paediatric rheumatology.
Citation: Hawwa AF, AlBawab A, Rooney M, Wedderburn LR, Beresford MW, et al. (2014) A Novel Dried Blood Spot-LCMS Method for the Quantification of
Methotrexate Polyglutamates as a Potential Marker for Methotrexate Use in Children. PLoS ONE 9(2): e89908. doi:10.1371/journal.pone.0089908
Editor: Maurizio D’Incalci, Istituto di Ricerche Farmacologiche Mario Negri, Italy
Received October 11, 2013; Accepted January 24, 2014; Published February 25, 2014
Copyright:  2014 Hawwa et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors would like to acknowledge the funding received from Arthritis Research UK (ARUK; Grant no. 19421; http://www.arthritisresearchuk.org/).
LW is partly supported by a grant from Great Ormond Street Childrens Chairty (Grant no. V1304). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: j.mcelnay@qub.ac.uk
Introduction
Juvenile idiopathic arthritis (JIA) and Juvenile dermatomyositis
(JDM) are chronic inflammatory disorders that affect children;
they have potentially serious consequences such as joint destruc-
tion and disability. The aetiology of JIA and JDM suggests the use
of anti-inflammatory and immunomodulatory agents to reduce or
stop the inflammatory process and achieve disease control [1,2].
The most important, first line therapy for both these diseases in
children and young people is methotrexate (MTX) [3–5]. MTX is
a folate antagonist that possesses potent anti-inflammatory activity;
it can be used alone or in combination with other medications
such as corticosteroids leading to control of the inflammation
process, and is able to slow disease progression [6]. However, due
to the wide spectrum of its side effects and inter-patient variability
of clinical response, tolerability and absorption, monitoring of
MTX metabolite concentrations is valuable clinically, in clinical
trials using MTX and can also be used to assess adherence to
prescribed regimens.
There is no clinical value in monitoring serum or plasma
concentrations of the drug itself since about 95% of a given dose is
metabolised within 24 hours of administration [7]. On the other
hand, monitoring methotrexate polyglutamates (MTXPGs), pro-
duced in the body from the metabolism of MTX, can act as a
biomarker to assess long-term therapy and adherence of MTX in
paediatric patients with JIA or JDM. MTXPGs are formed
intracellularly through sequential c-linkage of glutamic acid
residues to MTX by the enzyme folylpolyglutamate synthetase
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(FPGS), resulting in MTXPGs which are retained within red blood
cells long after MTX has been eliminated from the serum [8].
Evidence suggests that MTXPGs may also be associated with
efficacy and toxicity of the drug in the treatment of adults with
rheumatoid arthritis and investigators have advocated their
routine monitoring [9–11].
Several analytical methods have been described in the literature
to quantify methotrexate or individual methotrexate polygluta-
mates in different human biological matrices. Fluorescence
polarisation and enzyme immunoassay methods are available to
quantify methotrexate but are focused on the detection of MTX
and MTXPGs in plasma and urine and are useful when high dose
methotrexate is administered, e.g. in treatment of cancer but are
less efficient in quantifying the low concentrations presented when
low dose methotrexate is administered, as is the case in JIA and
JDM [12–14]. Radiochemical-ligand binding assays are sensitive
but are expensive and labour intensive [14]. For therapeutic drug
monitoring purposes, it has been shown that HPLC methods offer
suitable selectivity and sensitivity for the determination of
methotrexate and its polyglutamates, particularly when utilising
fluorescence detection after post-column photo or electrochemical
derivatisation [15–18]. Until very recently, however, LC-MS-MS
quantification of methotrexate received very little attention.
MTXPGs determination was first described by Chen and
colleagues who determined MTXPGs in Caco-2 cells [19]. The
first method described for the detection of MTXPGs in red blood
cells using MS detection was published in 2009, using positive
electro-spray ionisation [20].
To date, however, all of the existing methods for measuring
MTXPGs levels in patients necessitate blood withdrawal by
venipuncture which is invasive, requires relatively large blood
samples and needs clinical expertise. The goal of the present study,
therefore, was to develop and validate a simple bio-analytical
method for measuring MTXPGs in dried blood spots (DBS) which
can be applied to clinical practice (e.g. checking adherence to
prescribed MTX, absorption difficulties or other pharmacokinetic
deviations). The use of dried blood spots overcomes issues around
the volume of blood to be taken, is more convenient to transport to
the laboratory form remote sites e.g. GP surgeries, and can be used
for home sampling where parents or children themselves can
provide samples without the need for medical supervision. The
present study applies for the first time the novel DBS sampling
approach to methotrexate and compares the results obtained with
a conventional HPLC methodology for measuring MTXPGs in
red blood cells [17].
Materials and Methods
Ethics statement
The study was approved by the Office for Research Ethics
Committees in Northern Ireland (Ref no. 10/NIR03/33). Patients
were included in the study only after their parents or legal
guardians had been fully informed and had signed the study
consent form. In addition, verbal assent was obtained from older
children ($6 years) before enrolment into the study.
Reagents and chemicals
MTX was purchased from Sigma-Aldrich (Ayrshire, UK).
Methotrexate diglutamate (MTX-PG2), triglutamate (MTX-PG3),
tetraglutamate (MTX-PG4) and pentaglutamate (MTX-PG5) were
purchased from Schircks Laboratories (Jona, Switzerland). Aceto-
nitrile (ACN), ammonia solution (NH4OH) and methanol were of
HPLC grade and purchased from VWR International (Leicester-
shire, UK). Potassium hydroxide (KOH) and monobasic potassi-
um phosphate (KH2PO4) were purchased from VWR Interna-
tional (Leicestershire, UK). Mercaptoethanol and perchloric acid
were purchased from Sigma-Aldrich (Ayrshire, UK). Ammonium
bicarbonate (NH4HCO3), formic acid (CH2O2), hydrogen perox-
ide (H2O2) and Hanks’ balanced salt solution (HBSS) were
purchased from Sigma-Fluka (Ayrshire, UK). Lyophilised human
plasma was used as a source of the c-glutamyl hydrolase enzyme
and was purchased from Sigma-Aldrich (Ayrshire, UK). HPLC
grade water was produced using a Millipore Direct-QTM 5 water
purification system from Millipore (Watford, England). Guthrie
cards (Schleicher & Schuell 903) were purchased from Aston Ltd.
(Oldham, England) and Oasis solid phase extraction (SPE)
cartridges were obtained from Waters (Dublin, Ireland). All
reagents used in this work were of the highest available quality. All
mobile phase solutions were filtered under vacuum through FP-
Vericel (0.45mm) membrane filters from Sartorius (Epsom, UK)
and sonicated for 20 minutes prior to use.
Preparation of calibration standards
Stock solution (100 mM) of each of MTXPGs was prepared by
dissolving the appropriate amount of each compound in 1 ml of
100 mM KOH buffer, and then diluting with water. Working
standard solutions of different concentrations of MTXPGs were
prepared by appropriate dilutions of the stock solutions with water.
These working standards were then used for the preparation of
whole blood calibration standards of MTXPGs with final
concentrations ranging from 5-400 nM. The whole blood
(950ml) was spiked with a calibration mixture of equimolar
amounts of all polyglutamates (MTXPG1–5) to produce final total
MTXPGs concentrations of 400, 300, 200, 100, 62.5, 50, 25, 20
and 10 nM. These concentrations were chosen as they cover the
expected MTXPGs concentrations obtained in children receiving
MTX therapeutically. Stock solutions were stored at 280uC until
required. All working standard solutions were freshly prepared
from the stock prior to each analytical run. The QC samples at
concentrations of 2.5 (LLOQ), 25 (LQC), 125 (MQC) and
250 nM (HQC) for total MTXPGs and 4 (LLOQ), 10 (LQC),
25 (MQC) and 50 nM for individual polyglutamates were
prepared in a similar fashion.
Sample preparation and extraction
To prepare the blood spots, 30 mL of the spiked blood standards
were spotted onto Guthrie cards and allowed to dry overnight in
the dark at room temperature. The spotted Guthrie cards were
then placed in grease-proof envelopes, covered with aluminium
foil and stored in an airtight polypropylene container at 280uC
until analysis. RBC lysis occurs during the blood drying process
and the freeze-thaw cycle prior to analysis.
Determination of total MTXPGs after conversion to
MTX. For each DBS, a 6 mm diameter disc was punched
manually and placed in a polypropylene Eppendorf tube (2.0 mL
capacity) and mixed with 100 mL of water for 1 min. Total
MTXPGs were measured after conversion to MTX by adding
50 mL of reconstituted plasma, vortex-mixed for 30 sec, followed
by the addition of 100 mL of buffer containing 100 mM KH2PO4
and 150 mM mercaptoethanol. The mixture was then incubated
for 14 hours in the dark at 37uC. After incubation, 750 mL of
water was added to the mixture, vortex-mixed for 3 min, and
20 mL of 70% perchloric acid was then added and the whole
mixture centrifuged at 10,000 g for 10 min.
The clear supernatant was then subjected to solid phase
extraction (SPE) using Oasis MAX cartridges (1 ml/30 mg) on a
Waters Extraction Manifold (Waters, USA). The MAX cartridges
were conditioned using 1 mL of methanol followed by 1 mL of
Analysis of Methotrexate Biomarkers in DBS Samples
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water. The loaded sample was then washed in three steps firstly,
1 ml of 5% aqueous NH4OH was used followed by 1 ml of 100%
methanol and then 1 ml of 2% aqueous formic acid. Finally,
0.5 ml of 2% formic acid in water:methanol mixture (60:40) was
used for the elution step. The eluate obtained was evaporated to
dryness under a gentle stream of nitrogen at 37uC for 40 min,
reconstituted in 100 mL of mobile phase and 45 mL injected for
LC–MS analysis.
Determination of individual MTXPGs. A 6 mm diameter
disc was punched from each DBS and then transferred to a 2.0 ml
Eppendorf tube and vortex-mixed with 950 mL of water for 3 min.
An aliquot of perchloric acid (20 mL, 70%) was then added and
vortex-mixed for 30 sec. The tubes were then centrifuged at
10,000 g for 10 min, and the clear supernatant was then
transferred to Oasis MAX cartridge for extraction according to
the SPE procedure described above. The eluate was evaporated
under nitrogen for 40 minutes at 37uC and then reconstituted in
100 mL of mobile phase. A total volume of 45 mL of the final
extract was then injected onto the LC-MS-MS system.
Chromatographic and mass spectrometric (MS)
conditions
Chromatographic separation was achieved using reverse phase
chromatography with gradient elution. The chromatographic
system consisted of Waters Alliance 2795 Separation Module
coupled with a Waters Quattro Premier XE tandem quadrupole
mass spectrometer (Micromass, Manchester, UK) equipped with
an electrospray ionization (ESI) source. The instrument was
operated in positive ion mode. An Atlantis T3-C18 column
[15062.1 mm (i.d.); particle size, 3mm; Waters] protected with a
guard cartridge [20 mm62.1 mm; particle size, 3mm; Waters] was
used as the stationary phase. The LC system and the mass
spectrometer were both controlled by MassLynx 4.0 Software with
the QuanLynx Application Manager. The mobile phase consisted
of 10 mM NH4HCO3 buffer adjusted to pH 7.5 using formic acid
(A) and acetonitrile (B). Separation of the individual MTXPGs
(MTXPG1–5) was achieved using a linear gradient from 0% to
20% mobile phase B over 20 min (at a flow rate of 0.15 ml/min).
After 20 min, the mobile phase was returned to 100% mobile
phase A and re-equilibrated for 10 min. For the analysis of
MTXPGtotal, a gradient elution from 8% to 20% mobile phase B
over 10 min was utilised (at 0.15 ml/min) followed by 10 min re-
equilibration at 98% mobile phase A. For both analyses, the
column temperature was maintained at 30uC and the auto-
sampler at 4uC.
The different MS parameters including multiple reaction
monitoring (MRM) of precursor ions, product ions and their
collision energy parameters (Table 1) were optimised by direct
infusion of the individual analytes (syringe pump; 10ml/min)
dissolved in 80% A and 20% B, closely resembling the
chromatographic conditions. During the tuning, the intensity of
the base peak for each compound was monitored and adjusted to
maximum. A minimum of 2–3 transitions were used for each
compound. The transitions which resulted in the most selective
and abundant product ions were selected as the quantifier
transitions (Table 1). MRM mass spectrometer analysis mode
was used with the transition (455.4 R175.05) to capture the
MTXPGtotal signal. The following optimised MS operating
conditions were used: nebulising gas (nitrogen), 80 l/h; desolvation
gas (nitrogen), 800 l/h; source temperature, 135uC; desolvation
temperature, 450uC. The dwell time for each ion was set at 0.1 s.
Assay validation
The following parameters were evaluated for the validation of
the developed method [21].
Selectivity. The selectivity of the developed method was
determined by analysing blank blood spots from different sources
(n = 6) and spiked blood spots containing MTX and its poly-
glutamates at a final concentration that equals the determined
lower limit of quantification (LLOQ). Representative chromato-
grams were generated to show that endogenous components
present in the sample matrix were resolved from the analytes of
interest using the proposed extraction procedure and chromato-
graphic/mass spectrometric conditions. Potential interference
from concomitant medications commonly taken by paediatric
patients with JIA or JDM was investigated by analysing samples
which had been spiked with the appropriate drugs, e.g. folic acid,
prednisolone and omeprazole.
Linearity. The linearity of the method was established by
constructing calibration curves for both individual MTXPGs
(MTXPG1–5) and MTXPGtotal, on five consecutive days. Plots of
peak area (response) against analyte concentration were used. The
slope, the intercept and the correlation coefficient of each
calibration curve were determined.
Limit of detection and lower limit of quantification. The
following equation was used to estimate the limit of detection
(LOD) for each compound [21]:
LOD~
3:3s
S
where s is the standard deviation of the response (estimated from
the standard deviation of y-intercepts of regression lines), and S is
the slope of the standard curve.
Similarly, the lower limit of quantification (LLOQ) was
estimated using the following equation:
LLOQ~
10s
S
The estimated LOD and LLOQ were subsequently validated by
analysis of samples known to be near or prepared at those
concentrations.
Precision and accuracy. The accuracy and precision of the
developed method were determined from the analysis of DBS
samples spiked with MTXPGs at four concentrations representing
the LLOQ as well as the low, medium and high portions of the
standard curves (LQC, MQC and HQC). Intra-day accuracy and
precision were calculated on a single day using five replicates at
each concentration level. Inter-day bias and precision were
calculated using three replicates at each concentration level over
five consecutive days. The QC samples were analysed against the
calibration curve and the concentrations obtained were compared
with the known value.
The accuracy and precision of the method were expressed as the
mean percentage relative error (%RE) and percentage coefficient
of variation (%CV), respectively. The mean accuracy (%RE) and
precision (%CV) should be within 15% of the actual value except
for LLOQ which should not deviate by more than 20% [22].
Recovery and Matrix effect. The efficiency of the extrac-
tion procedure was determined by the analysis of BDS samples
spiked with MTXPGs at three concentrations (LQC, MQC and
HQC). Five replicates at each concentration level were extracted
and analysed and the responses compared with those of non-
extracted standards, which represent 100% recovery.
Analysis of Methotrexate Biomarkers in DBS Samples
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Matrix effect or ion suppression caused by the biological matrix
[23] was assessed using the post-column infusion method where an
equimolar solution of MTXPs (total concentration of 50 nM) was
continuously infused post-column at a rate of 10 mL/min through
a T joint and mixed with the column effluent of processed blank
DBS samples injected into the column to analyse the potential
influence of eluting matrix components on analyte responses. The
absolute matrix effect was also measured quantitatively by
comparing the ion counts of post-extraction spiked samples with
those from pure solutions at three pre-determined concentrations
of MTXPGs (LQC, MQC and HQC). If the ratio is ,85% or
.115%, an exogenous matrix effect is implied [24].
Stability. A stability study of MTX and its metabolites over a
two month period was conducted to ensure that patient samples
are stable during shipping and storage, prior to analysis. The
stability of samples during storage was determined by analysing
DBS samples containing MTXPGs at high and low QC levels
(n = 5 replicates) weekly over two months after storage at 280uC
or at room temperature (25uC). For each sample, the ratio of the
two concentrations measured for each analyte before and after
storage, was calculated. The mean ratio and standard deviation for
each analyte was then determined.
The effect of the haematocrit on spreadability of blood on
Guthrie cards. In order to examine the effect of varying
haematocrit (Hct) levels on the spreadability of blood when
spotting DBS samples, various Hct levels of whole blood were
created by adding plasma to or removing plasma from fresh
human blood. Blood was prepared at Hct levels of 30, 40, 45, 50
and 55% and aliquots (30 mL) of the prepared blood samples were
then spotted on Guthrie cards and allowed to dry as described
previously (n = 8). The spreadability was determined by measuring
the surface area of the dried blood spot formed using ImageJ
image analysis software.
Method comparison
In the present study, MTXPG DBS levels measured by the
developed LC/MS/MS procedure were compared to those
measured in packed RBCs by a conventional HPLC method
developed and validated in our laboratory. The developed HPLC
method was based on that reported by Dervieux et al. [17] because
it has been widely used in clinical studies that have served as the
basis for proposing treatment-related therapeutic ranges for
MTXPGs. The extraction procedure described by Derviuex et al.
is rapid, easy to perform and allows simultaneous determination of
individual MTXPGs or total MTXPGs. However, rapid extrac-
tion has led to less than optimal clean-up of the samples which
result in the retention of unremoved endogenous components on
the guard column and subsequently on the column. Due to these
difficulties a combined method involving protein precipitation and
SPE clean-up procedure was developed to enhance the removal of
endogenous substances from the samples prior to HPLC analysis.
Briefly, 50 mL RBC haemolysate were prepared and extracted as
detailed by Dervieux et al. but the supernatant was diluted with
water up to 1 ml and then subjected to solid phase extraction using
Oasis MAX cartridges as described in section 2.3.1. The eluate
was evaporated under nitrogen for 40 minutes at 37uC and then
reconstituted in 100 mL of mobile phase. A total volume of 50 mL
was then injected onto the HPLC system. The chromatographic
method employed reverse phase chromatography with post-
column photooxidation and fluorometric detection. Separation
was achieved using Waters XBridge C18 column (25064.6 mm
ID, 5mm) fitted with a 20 mm guard of similar chemistry, both
maintained at 40uC. Emission and excitation wavelengths were
similar to those selected by Dervieux et al [17]. Since the HPLC
method involved some modifications to that reported by Dervieux
et al., it was revalidated in our laboratory according to the ICH
guidelines [21]. Results showed that the developed method was
linear over the concentration range studied (5–400 nM of
MTXPGs) with a correlation coefficient .0.996 for all analytes.
Accuracy (% RE) and precision (% CV) values for within and
between day were ,20% at the LLOQ and ,15% at all other
concentrations tested. The LLOQ of the method was validated at
4.0 nM for each polyglutamate and 4.5 nM for total MTXPGs.
Clinical application
The developed assays of MTXPGs in DBS and packed RBCs
were applied to the analysis of DBS finger prick samples and whole
blood samples collected from children with JIA or JDM who were
receiving MTX weekly doses (oral or subcutaneous) for at least two
months. Whole blood samples (1 ml) were taken by venepuncture
from each patient at the same time the DBS sample was collected.
Packed RBCs were obtained from the whole blood sample after a
centrifugation step to separate plasma and buffy coat from RBCs,
the RBCs were washed twice with two volumes of Hanks’
balanced salt solution (HBSS) and packed RBCs were then stored
at 280 until analysis. MTXPGs concentrations measured from
DBS and packed RBC samples were then compared utilising
Bland-Altman plots [25].
Statistical methods and data analysis
Linearity of the assay was calculated by linear regression
analysis. Standard curve regression analysis was performed by
MassLynx 4.0 software (Waters Corporation, USA). The level of
agreement between the developed LC-MS method and the
conventional HPLC method based on that reported by Dervieux
et al. was examined using Bland-Altman plots generated with
GraphPad Prism (ver. 5) software; 95% of MTXPGs levels
resulting from the two sampling methods should not exceed 6 two
times the standard deviation of the mean difference in order to
pass the test [25]. Means and standard deviations were calculated
Table 1. MRM parameters for the analysis of MTXPGs.
compound Parent ion (m/z) Product ion (m/z) Cone voltage (V) Collision energy (V)
MTXPG1 455.40 175.05 21.00 36.00
MTXPG2 584.40 175.05 26.00 50.00
MTXPG3 713.40 175.05 38.00 56.00
MTXPG4 842.30 175.05 40.00 62.00
MTXPG5 971.60 175.05 46.00 67.00
doi:10.1371/journal.pone.0089908.t001
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using Microsoft Excel 2010 software (Microsoft Corporation,
USA).
Results and Discussion
LCMS determination of MTXPGs in DBS samples
The developed method was found to be selective for MTX and
its metabolites in the presence of endogenous matrix components.
Representative MRM chromatograms, obtained following the
sample treatment procedure outlined above, demonstrated the
resolution of individual MTX polyglutamates (MTXPG1–5) and
total MTXPGs (after conversion to MTXPG1) from the biological
matrix of blank DBS samples (Figure 1). The basic pH of the
mobile phase (buffered at 7.5) resulted in proportionally higher
ionization of the carboxylate groups of longer-chain polygluta-
mates, resulting in elution inversely proportional to polyglutama-
tion number. The performance of several chromatographic
columns (Waters Xbridge C18, Waters Atlantis T3 and Sequant
HILIC) was tested for the separation of MTXPGs; however,
baseline separation with the highest efficiency and peak symmetry
was achieved with Atlantis T3 column. This was particularly true
for longer chain polyglutamates as the column provided enhanced
retention of such very polar compounds while exhibiting good
peak shape and efficiency. The total run time for determining the
individual MTXPGs was 20 min with all peaks of interest being
eluted within 18 min. However, when total MTXPGs was
determined, the total run time was only 10 min with the peak of
interest (MTXPG1) being eluted within 8 min.
A series of experiments were conducted to ascertain the most
appropriate solvent and method for extraction. Following these
studies, it was concluded that extraction of DBS with water and
protein precipitation using perchloric acid resulted in high and
reproducible recoveries. This was followed by The SPE clean up
procedure. Strong retention of all MTXPGs was obtained by the
use of Oasis MAX SPE cartridges which contain a mixed-mode
polymeric sorbent that has been optimized to achieve higher
selectivity and sensitivity for extracting acidic compounds with
anion-exchange groups. Clean extracts were eluted and evaporat-
ed to dryness and reconstituted in a small volume prior to analysis.
Positive ESI mode was chosen for the determination of MTXPGs
since it produced a more favourable signal to noise ratio, ionized
MTXPGs more efficiently and resulted in linear regression curves
for the analytes. Fragmentation of MTXPGs using collision
induced dissociation at the optimized MS parameters resulted in
abundant product ions at m/z 308.10 and 175.05. The latter
product ion was selected to obtain the maximum selectivity for all
MTXPGs under the MRM spectra since an unidentified
endogenous compound that forms a 308.10 fragment was
observed resulting in a peak that could interfere with MTX in
the MRM channel.
The selectivity of method was investigated by analysing DBS
samples collected from untreated healthy subjects and also from
patients with JIA or JDM. No interferences were observed at the
retention times of MTPGs. Additionally, no interferences were
observed from the drugs commonly given to the study patients (see
earlier).
Method validation
Calibration curves demonstrated a linear relationship between
peak area and concentration with correlation coefficients .0.995
for all five individual polyglutamates (MTXPG1–5) and for
MTXPG1 formed after enzymatic conversion of MTXPGtotal.
The mean correlation coefficient, slope and intercept values
describing the calibration curves are presented in Table 2. Within
and between day accuracy and precision were determined for each
of the individual MTXPGs and MTXPGtotal during the 5-day
validation experiments at low, middle and high QC concentra-
tions. Precision and accuracy were found to be within6 15% at all
QC concentrations as shown in Table 3. The limits of detection
for individual MTXPGs and MTXPGtotal were determined as 1.6
and 1.5 nM, respectively. The corresponding LLOQ values were
calculated as 5 and 4.5 nM, respectively. These values were
Figure 1. Representative MRM chromatograms of a blank DBS sample (A), DBS spiked with MTXPGs (final total concentration of
100 nM) subjected to enzymatic conversion to MTXPG1 (B), and DBS sample spiked with MTXPG1–5 measured individually at a
final concentration of 100 nM each (C).
doi:10.1371/journal.pone.0089908.g001
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validated by analysis of a suitable number of samples known to be
near the calculated LLOQ (4 and 2.5 nM for individual and total
MTXPGs, respectively) [26,21]. The precision and accuracy at
these concentrations were within the acceptable limits of 620%
(Table 3).
The mean extraction recoveries were 71% for MTXPG1, 70%
for MTXPG2, 72% for MTXPG3, 44% for MTXPG4, 49% for
MTXPG5 and 70% for MTXPGtotal. Although lower recoveries
were obtained for longer-chain polyglutamates (MTXPG4–5), they
were reproducible. Such values compared favourably with recently
published methods utilising SPE for extracting MTXPGs [20].
Although the extraction of extracellular MTXPGs in spiked
standards might not be fully comparable with the extraction of
intracellular glutamates in patient samples, any potential differ-
ence was minimised in the present study by haemolysing the RBC
cells in both standard and patient DBS samples through blood
drying and freeze-thawing of samples prior to analysis. The matrix
effect, defined as the analyte ionisation suppression or enhance-
ment due to the presence of endogenous components within the
biological matrix [24], was assessed using a qualitative method as
shown in Figure 2, which present MRM traces obtained during
the post-column infusion experiment. The results indicate that
there were no significant baseline variations at the retention times
of MTXPGs. In addition, a quantitative method revealed that the
estimated matrix effect (% ME) on all MTXPGs was within the
acceptable limits of 615%, which indicates the lack of any major
ion suppression or enhancement for MTXPGs in this method.
The result of the stability studies indicated that MTXPGs in the
DBS matrix were stable at 280uC and room temperature (25uC)
over a 2-month storage period. The values found were 0.9560.06
for MTXPG1, 1.0960.02 for MTXPG2, 0.9860.07 for
MTXPG3, 1.0760.07 for MTXPG4, 1.0160.10 for MTXPG5
and 0.9860.06 for MTXPGtotal at 280uC and 0.9460.08,
0.9060.09, 0.9660.11, 0.8860.07, 0.8660.07 and 0.9360.08
for these compounds at room temperature, respectively, indicating
stability of MTXPGs at the storage conditions employed.
Investigation of the distribution of MTXPGs throughout the
blood spot applied to the Guthrie card was investigated as
described by our group in a previous study [27]. The results
indicated that the analytes were evenly distributed throughout the
DBS. In addition, the effect of varying Hct levels on the size of the
formed spots was assessed. The results demonstrated minimal
effect of Hct within the range of 30–55% on the measured surface
area of the DBS sample formed when either fresh or haemolysed
blood was used (Figure 3). Each of the measured areas displayed a
difference of less than 65% from that measured at the middle Hct
level (45%) within the range studied. Haemolysed blood showed a
slight increase in blood spot diameter compared to fresh blood
with a similar HCT, though the increase in the blood spot size
from haemolysed blood was less than 5%.
Method comparison and analysis of patient samples
The developed LCMS and HPLC assays have been used to
determine MTX and its polyglutamates in clinical samples from a
cohort of 47 children with JIA/JDM who were receiving low dose
MTX treatment (10–20 mg). Matched erythrocyte and DBS
samples (n = 94) were obtained in an effort to develop a
comparison between the two developed methods. Measured
MTXPG levels were within the ranges quoted in literature
[28,17,20]; MTXPG3 was the most predominant species (38.6% of
the sum of MTXPG1–5) which is consistent with previous
publications [17,20].
To allow comparison with DBS samples, the measured
MTXPG concentrations in RBC samples were first converted
into the equivalent whole blood concentrations (by taking into
account the individual Hct values for each patient). Bland-Altman
plots of the difference between DBS and RBC concentrations for
each MTXPG were then examined (Figure 4). The mean (d) and
standard deviation (s) of the difference between the two matched
readings were calculated to determine the equivalence between the
two methods; since more than 95% of the plotted points fell within
d - 2s and d + 2s, the suitability of the DBS analytical method to
analyse patient samples was confirmed. Correlation plots between
concentrations obtained by the two alternative methods revealed
that the difference between the two methods was minimal for
short-chain glutamates (MTXPG1–2) [as evidenced by a slope of
1.09 (r = 0.81 for MTXPG1) and a slope of 1.03 (r = 0.84 for
MTXPG2)] but increased in magnitude for longer-chain gluta-
mates (MTXPG3–4) [slope= 1.22, r = 0.83 for MTXPG3 and
slope = 1.29, r = 0.84 for MTXPG4] with measured concentrations
being slightly higher in DBS samples. This suggests that longer-
chain glutamates were more easily extracted from DBS compared
to erythrocyte samples. We speculate that this is due to enhanced
lyses of RBCs when dried on Guthrie cards. Dervieux et al. have
stated that a higher number of glutamic residues might affect the
stability, and therefore, the recovery of MTXPG moieties during
the deproteinization step of the conventional HPLC method. This
is of particular clinical interest since longer-chain MTXPGs are
associated with increased potency over short-chain glutamates. A
typical patient chromatogram from an extracted DBS sample is
shown in Figure 5.
Table 2. Results of the five calibration curves for MTXPGs; calibration points (nmol/L)a, slope6SD, intercept and correlation
coefficient of the standard curves.
Compound C1 C2 C3 C4 C5 C6
Slope
(mean±SD)
Intercept
(mean±SD)
Correlation
coefficient (r)
MTXPG1 5 (4.560.5) 12.5 (11.361.6) 20 (19.460.7) 40 (38.762.4) 60 (59.960.1) 80 (81.061.3) 187.8617.9 218.963.4 .0.998
MTXPG2 5 (4.860.6) 12.5 (11.461.7) 20 (20.560.8) 40 (39.361.9) 60 (60.060.1) 80 (80.461.1) 80.1611.2 49.266.1 .0.999
MTXPG3 5 (4.860.5) 12.5 (11.761.2) 20 (20.260.5) 40 (39.962.5) 60 (59.760.2) 80 (80.261.4) 46.464.2 33.463.9 .0.998
MTXPG4 5 (4.460.7) 12.5 (11.261.4) 20 (19.361.7) 40 (39.861.6) 60 (60.160.8) 80 (79.360.7) 30.664.4 0.5260.2 .0.999
MTXPG5 5 (4.960.5) 12.5 (12.061.5) 20 (20.462.2) 40 (38.863.5) 60 (59.961.2) 80 (80.661.9) 7.661.1 17.962.7 .0.995
MTXPGtotal 10
(10.961.8)
20 (21.860.6) 50 (47.861.4) 100 (90.563.7) 200 (190.963.9) 400 (406.962.0) 25.664.9 2113.9612.8 .0.998
aSpiked concentrations of calibration standards [measured concentrations (mean6SD) are shown within brackets].
doi:10.1371/journal.pone.0089908.t002
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Conclusion
The development and validation of LCMS method designed for
the determination of MTXPGs in DBS samples has been
described. To our knowledge, this is the first report describing
the simultaneous determination of MTX and its polyglutamates in
dried blood spots. This novel sampling technique coupled with
LC-tandem MS detection system led to a selective and sensitive
method appropriate for use in very low volume paediatric samples
(approximately 12ml of whole blood). The developed method was
shown to be linear, accurate, precise and reliable. The sample
treatment procedure is simple, involving protein precipitation
followed by SPE clean-up and analyte reconstitution. The
analytical method shown here has been successfully applied for
the analysis of DBS samples obtained from finger pricks in
paediatric patients with JIA and JDM. The methodology has a
potential for application in a range of clinical studies (e.g.
pharmacokinetic evaluations or medication adherence assessment)
since it is minimally invasive and easy to perform, potentially
allowing parents to take blood samples at home. The feasibility of
using DBS sampling to measure MTX in children, therefore, can
be of major value for future clinical trials or clinical care in
Figure 2. Individual MRM traces obtained upon injection of processed DBS with blank blood into a column post-infused with
MTXPG solutions; chromatograms indicated no matrix effect over the time of analysis.
doi:10.1371/journal.pone.0089908.g002
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Figure 3. Effect of varying blood haematocrit on the measured area of DBS spot formed (mean area ± SD; n=8).
doi:10.1371/journal.pone.0089908.g003
Figure 4. Bland-Altman plots comparing MTXPG1–5 and MTXPGtotal concentrations in DBS versus RBCs in all patient samples
investigated (n=94).
doi:10.1371/journal.pone.0089908.g004
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paediatric rheumatology patients and indeed further studies,
particularly relating to methotrexate absorption and medication
adherence are at an advanced stage of development by the group.
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